e randomized, multi-center, double-blind, placebo controlled study of 2,022 patients undergoing PCI after pretreatment with clopidogrel were randomized to receive abciximab or placebo. The researchers measured for 30-day combined incidence of death, heart attack or urgent revascularization, as well as bleeding complications. The trial results show the role of the combination - intensive clopidogrel pretreatment plus abciximab - during PCI for ACS. They will enable us to know whether patients with ACS or any subset of them can benefit from this combination.

Dr. Kastrati will present the results of the "Prospective, Double Blind, Placebo-Controlled Trial of Glycoprotein IIb/IIIa Inhibition with Abciximab in Patients with Acute Coronary Syndromes Undergoing Stenting After Pretreatment with a High Loading Dose of Clopidogrel" (ISAR-REACT 2) study on Monday, March 13, at 2:40 p.m.

'"/>


14-Mar-2006

Page: 1 2
Related medicine news :

1. FDA approves Dey, L.P.s Perforomist inhalation solution for maintenance treatment of COPD
2. Internal medicine organizations survey internists on maintenance of certification
3. ASH Self-Assessment Program receives approval for maintenance of certification credit
4. Future therapies for stroke may block cell death
5. Antifolate therapies found effective against certain type of malaria
6. Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer
7. A sweet step toward new cancer therapies
8. Psychological therapies for common anxiety disorder not readily available in primary care settings
9. About 5 percent of adults with insomnia use alternative therapies
10. Combined therapies may boost immune response and long-term protection against brain tumors
11. New hope in cancer vaccines emerges as novel therapies are developed and tested